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See Article, pages 380–388Screening for hepatocellular carcinoma (HCC) in the population
at risk (namely patients with liver cirrhosis) is now an estab-
lished practice [1]. It aims to detect tumors at an early stage so
that treatments that may provide a cure for the cancer can be
implemented. Years ago, this was seen as an impossible goal
and the efforts of those working in the ﬁeld of clinical liver cancer
were seen as unfruitful. However at present, liver resection,
transplantation, and ablation are conventional treatments in clin-
ical practice and the current debate centers around which treat-
ments should be given as a priority to patients diagnosed with
early HCC. The controversy affects only those individuals who
stand to beneﬁt from all treatments. It is clear that patients with
early HCC in decompensated cirrhosis will be better served by
transplantation if there are no contraindications for it because
of age and/or co-morbidities. A commonly held belief is that
the depicted uncertainty is easily solved by developing a large,
prospective, randomized clinical trial comparing the three
options or at least two of them. There are a small number of trials
with limited sample sizes and heterogeneous patient populations
which have not solved the debate in a robust manner. For a trial
to be fully informative it needs to recruit patients whose proﬁle
makes them suitable candidates for all three options, as it would
not be appropriate to compare suboptimal candidates for surgery
with the best candidates for ablation. Since the outcome of liver
transplantation is not affected by liver function or by tumor bur-
den if it is still within the Milan criteria [2,3], the key would be to
deﬁne the optimal candidates for resection and ablation, and then
select as the target population for the trial the proﬁle that is
shared as optimal for both options and stratify them according
to the most relevant. Several studies have shown that nodule size
is the major parameter that predicts the success of ablation (the
cut-off is around 3 cm in size) [4–7], while presence of more than
one nodule also affects efﬁcacy, recurrence, and ultimately, sur-
vival [8,9]. Hence, a valid trial should be restricted to this size
and if aiming for optimal candidates, should only include solitary
HCC. Data for selection of the best candidates for resection areJournal of Hepatology 20
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E-mail address: jbruix@clinic.ub.es (J. Bruix).also known: absence of clinically signiﬁcant portal hypertension
reﬂected by a hepatic vein pressure gradient <10 mm Hg and sol-
itary HCC deﬁne the optimal population both in the West [10]
and the East [11]. Following these comments, a trial comparing
resection vs. ablation should optimally include patients without
clinically signiﬁcant portal hypertension diagnosed with solitary
HCC <3 cm. The end-point of the trial should be survival, and
available data in cohort studies indicate that we could have a
70% survival at ﬁve years in both arms. Accordingly, the trial
could be designed as a non-inferiority trial, with the expectation
of providing a basis for suggesting that ablation should be the
ﬁrst choice and leave resection for failures. Since the results for
ablation are signiﬁcantly better in HCC 62 cm [4,12] it would
be advisable to stratify patients according to this size limit.
Now that the trial design is deﬁned, should we ask if such a trial
feasible? The answer is clearly negative. The sample size for such
a trial would exceed 1000 patients and the study duration would
surely last at least 5 years. Liver cancer is not as prevalent as colo-
rectal, breast, or lung cancer and the stratum of patients targeted
is very narrow. In the BCLC group, this type of patient proﬁle
involves less than 1% of the global HCC population [13] and the
proportion should be almost the same in most western referral
centers where state of the art surgical and ablative skills are
available. Hence, the study should be multi-centric and interna-
tional and thus requires that a vast monitoring effort be in place
for several years. As a whole, the budget projection for such a
study would be extremely expensive and any assessment would
classify the study as unfeasible and/or not robust enough to reach
an unequivocal answer to the hypothesis posed.
In addition to the challenges highlighted above, the investiga-
tors would also have to use the optimal ablation technique and
maintain it in place, even if new technologies are developed
while the trial is running. This has been a very active research
front, and as it frequently occurs with device development, the
request for robust assessment is less intense than for pharmaceu-
tical agents. The ﬁrst technique that opened ablation activity for
HCC patients consisted in the repeated injection of ethanol
through a ﬁne needle inserted into the HCC under US guidance.
After initial proof of concept and wide application in several
Units, it was clear that tumor size was the main determinant of
success. Ethanol inﬁltration rarely affected all the mass beyond10 vol. 52 j 310–312
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3 cm in size and the presence of intratumoral septa prevented
diffusion of the ethanol within the HCC [14]. Acetic acid injection
was suggested to be an alternative with better diffusion capacity
[15], but the real breakthrough came with the development of
radiofrequency (RF) [6]. Tumor necrosis was achieved by delivery
of heat and all the issues related to diffusion of liquid were gone.
In addition, RF has a more predictable necrotic capacity and with
less treatment sessions achieves the same therapeutic action
[7,16–19]. Hence, RF has become the preferred mode of ablation
and ethanol has lost its primacy [20]. Other techniques with
promising activity such as microwave, cryotherapy, high inten-
sity focused ultrasound (HIFU) are far behind in the competition.
Is the primacy of RF justiﬁed with the available data and for all
HCC amenable to be ablated? This is the question posed by Ger-
mani et al. in the meta-analysis published in this issue of the
Journal of Hepatology [21]. Some randomized trials have sug-
gested that this is indeed the case [7,18], but as usual, it might
be argued that design details and sample size limitation may
allow for some suboptimal evidence. It is in this type of setting
that a meta-analytical approach helps to frame the evidence
and critically exposes the limitations of the available data. The
results conﬁrm that the evaluation of different techniques is
not fully robust since the nature of the studies to evaluate them
is not homogeneous. Nevertheless, with all the concerns, it
appears that the assumption of RF as the ﬁrst line technique is
not incorrect, but this does not mean that ethanol or acetic acid
injection is to be dismissed. The data with acetic acid are limited,
but the results of ethanol injection in HCC 62 cm in size are not
different from those obtained by RF. Hence, the advantage of RF
emerges when the success of ethanol is limited by septa and it
fails to affect the entire mass. A second reason for better local
control of the disease beyond this size is that RF may induce a
safety ablation margin that would cause necrosis of already exist-
ing satellites and/or microscopic vascular invasions. Distant
recurrence would appear whatever technique is in place, but in
terms of primary tumor removal, RF would compete better with
resection. Does this have an impact on survival or is it just a futile
effort to enhance therapeutic response without long term conse-
quences? Several investigations indicate that initial response to
ablative treatment is related to improved survival [4] and the
intensity of tumor necrosis also correlates with improved sur-
vival after TACE [22,23]. Accordingly, for ablation therapy to
inﬂuence survival it is key to secure complete tumor necrosis
as early as possible.
Does this mean that ethanol injection is not useful? Not at all!
As said previously, in HCC 62 cm both ethanol and RFA are
highly effective and beyond this size limit ethanol and RF will
work simultaneously for a short period. Some tumors are located
at risky sites and RFA treatment can incur severe complications
[24]. In addition, in tumors larger than 2 cm in size, initial RF
may leave a tiny nest of viable tissue that will easily be ablated
by ethanol with a relevant saving of resources [20].
In summary, ablation is a powerful therapeutic tool for
HCC patients and the available techniques have reached matu-
rity with deﬁned capacities and limitations. The current contro-
versy is not about the effectiveness of ablation, but rather
about how to prevent disease recurrence, a challenge that also
affects surgical resection and limits long term survival. Hope is
placed in the future use and efﬁcacy of molecular therapies; how-
ever, such a breakthrough will take years to become a reality. In
the meantime, data collected in studies like the one by GermaniJournal of Hepatology 201et al. serve to structure conventional clinical decision making.
Such studies provide the necessary scientiﬁc background to
establish the assumptions needed for the design of clinical trials
that assess new agents for the prevention of recurrence.
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